Patents by Inventor Timothy Collier
Timothy Collier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11940452Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: GrantFiled: October 29, 2019Date of Patent: March 26, 2024Assignee: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 11434501Abstract: This invention relates to the prevention and treatment of neurodegenerative diseases by administering compositions that increase the activity of a small proline-rich repeat 1 A protein (Sprr1A), or derivative thereof to the brain. Specifically, the compositions may comprise a nucleic acid molecule encoding a Sprr1A protein or a biologically-active portion thereof. The neurodegenerative disease may be Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.Type: GrantFiled: August 27, 2015Date of Patent: September 6, 2022Assignee: Board of Trustees of Michigan State UniversityInventors: Jack W. Lipton, Nicholas Kanaan, Timothy Collier
-
Publication number: 20210373038Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: ApplicationFiled: July 2, 2021Publication date: December 2, 2021Applicant: CLEVELAND HEARTLAB, INC.Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Patent number: 11061039Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: GrantFiled: December 4, 2018Date of Patent: July 13, 2021Assignee: Cleveland Heartlab, Inc.Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Publication number: 20210132090Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.Type: ApplicationFiled: January 7, 2021Publication date: May 6, 2021Applicant: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 10921331Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.Type: GrantFiled: July 21, 2017Date of Patent: February 16, 2021Assignee: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20200116744Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: ApplicationFiled: October 29, 2019Publication date: April 16, 2020Applicant: CLEVELAND HEARTLAB, INC.Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 10466260Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: GrantFiled: October 20, 2017Date of Patent: November 5, 2019Assignee: Cleveland Heartlab, Inc.Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20190250177Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: ApplicationFiled: December 4, 2018Publication date: August 15, 2019Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Patent number: 10151764Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: GrantFiled: May 15, 2015Date of Patent: December 11, 2018Assignee: The Cleveland HeartLabInventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Patent number: 10144932Abstract: Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein (“Nurr1”). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.Type: GrantFiled: June 5, 2015Date of Patent: December 4, 2018Assignee: Board of Trustees of Michigan State UniversityInventors: Fredric P. Manfredsson, Jack W. Lipton, Nicholas Kanaan, Timothy Collier, Kathy Steece-Collier, Caryl E. Sortwell
-
Publication number: 20180031586Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: ApplicationFiled: October 20, 2017Publication date: February 1, 2018Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20180024152Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.Type: ApplicationFiled: July 21, 2017Publication date: January 25, 2018Inventors: Cory Bystrom, Timothy Collier
-
Patent number: 9810702Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: GrantFiled: September 18, 2015Date of Patent: November 7, 2017Assignee: THE CLEVELAND HEARTLAB, INC.Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20170283829Abstract: This invention relates to the prevention and treatment of neurodegenerative diseases by administering compositions that increase the activity of a small proline-rich repeat 1 A protein (Sprr1A), or derivative thereof to the brain. Specifically, the compositions may comprise a nucleic acid molecule encoding a Sprr1A protein or a biologically-active portion thereof. The neurodegenerative disease may be Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.Type: ApplicationFiled: August 27, 2015Publication date: October 5, 2017Inventors: Jack W. Lipton, Nicholas Kanaan, Timothy Collier
-
Publication number: 20170198295Abstract: Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein (“Nurr1”). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.Type: ApplicationFiled: June 5, 2015Publication date: July 13, 2017Inventors: Fredic P. Manfredsson, Jack W. Lipton, Nicholas Kanaan, Timothy Collier, Kathy Steece-Collier, Caryl E. Sortwell
-
Publication number: 20160084856Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.Type: ApplicationFiled: September 18, 2015Publication date: March 24, 2016Inventors: Cory Bystrom, Timothy Collier
-
Publication number: 20150331000Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.Type: ApplicationFiled: May 15, 2015Publication date: November 19, 2015Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
-
Patent number: 7595295Abstract: The invention provides methods for promoting neuron survival in patients by administering pleiotrophin, or nucleic acids encoding pleiotrophin. Uses of the invention include promoting neuron graft survival, preventing or reducing nervous system degeneration, and restoring the nervous system, in patients suffering from, or at risk for, neurodegenerative disorders.Type: GrantFiled: February 25, 2005Date of Patent: September 29, 2009Assignee: Rush University Medical CenterInventors: Deanna Marchionini, Timothy Collier
-
Publication number: 20060193831Abstract: The invention provides methods for promoting neuron survival in patients by administering pleiotrophin, or nucleic acids encoding pleiotrophin. Uses of the invention include promoting neuron graft survival, preventing or reducing nervous system degeneration, and restoring the nervous system, in patients suffering from, or at risk for, neurodegenerative disorders.Type: ApplicationFiled: February 25, 2005Publication date: August 31, 2006Inventors: Deanna Marchionini, Timothy Collier